| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Patrick Maison, Anne-Isabelle Tropeano, Isabelle Macquin-Mavier, Andrea Giustina, Philippe Chanso. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. The Journal of clinical endocrinology and metabolism. vol 92. issue 5. 2007-06-06. PMID:17311857. |
impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. |
2007-06-06 |
2023-08-12 |
Not clear |
| J Lindhol. Growth hormone: historical notes. Pituitary. vol 9. issue 1. 2007-04-03. PMID:16703403. |
in the same period both gh releasing and inhibiting hormones were identified and an analogue of somatostatin had evolved into the first effective pharmacological treatment for acromegaly. |
2007-04-03 |
2023-08-12 |
human |
| Michael Madsen, Esben Boll Matthiesen, Per Løgstrup Poulsen, Jørgen Weeke, Jens Astrup, Jens Otto Lunde Jørgense. [Treatment of acromegaly in Aarhus University Hospital. A retrospective investigation of the period from 1994 to 2004]. Ugeskrift for laeger. vol 169. issue 10. 2007-03-20. PMID:17359734. |
traditional treatment of acromegaly comprises surgery and somatostatin analogs (sa), which however is effective in no more than 80%. |
2007-03-20 |
2023-08-12 |
Not clear |
| Jens Otto Lunde Jørgensen, Ulla Feldt-Rasmussen, Jan Frystyk, Jian-Wen Chen, Lars Østergård Kristensen, Claus Hagen, Hans Ørsko. [Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist]. Ugeskrift for laeger. vol 169. issue 10. 2007-03-20. PMID:17359735. |
[medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist]. |
2007-03-20 |
2023-08-12 |
Not clear |
| Jens Otto Lunde Jørgensen, Ulla Feldt-Rasmussen, Jan Frystyk, Jian-Wen Chen, Lars Østergård Kristensen, Claus Hagen, Hans Ørsko. [Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist]. Ugeskrift for laeger. vol 169. issue 10. 2007-03-20. PMID:17359735. |
we tested the effect of co-treatment of acromegaly with a somatostatin analogue (sa) and a growth hormone receptor antagonist (gha). |
2007-03-20 |
2023-08-12 |
Not clear |
| Françoise Galland, Peter Kamenicky, Hélène Affres, Yves Reznik, Dominique Pontvert, Yves Le Bouc, Jacques Young, Philippe Chanso. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. The Journal of clinical endocrinology and metabolism. vol 91. issue 12. 2007-01-25. PMID:16984995. |
mccune-albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. |
2007-01-25 |
2023-08-12 |
Not clear |
| T Lucas, R Astorg. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clinical endocrinology. vol 65. issue 3. 2007-01-12. PMID:16918950. |
depot somatostatin analogues are well accepted as either adjuvant or primary therapy for acromegaly, and their long dosage intervals facilitate adherence to treatment. |
2007-01-12 |
2023-08-12 |
Not clear |
| E Ferrante, C Pellegrini, S Bondioni, E Peverelli, M Locatelli, P Gelmini, P Luciani, A Peri, G Mantovani, S Bosari, P Beck-Peccoz, A Spada, A Lani. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocrine-related cancer. vol 13. issue 3. 2007-01-08. PMID:16954443. |
somatostatin analogs currently used in the treatment of acromegaly and other neuroendocrine tumors inhibit hormone secretion and cell proliferation by binding to somatostatin receptor type (sst) 2 and 5. |
2007-01-08 |
2023-08-12 |
human |
| Filip Gołkowski, Monika Buziak-Bereza, Bohdan Huszn. [Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly]. Przeglad lekarski. vol 63. issue 3. 2007-01-04. PMID:16967698. |
[evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly]. |
2007-01-04 |
2023-08-12 |
human |
| Eva Horvath, Kalman Kovac. Pathology of acromegaly. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047379. |
the medical therapy of acromegaly is reviewed briefly, including long-acting somatostatin analogs and pegvisomant, a gh receptor blocker. |
2006-11-21 |
2023-08-12 |
Not clear |
| George Tolis, Nicholas G Angelopoulos, Eugenia Katounda, Grigorios Rombopoulos, Victoria Kaltzidou, Dimitrios Kaltsas, Anthi Protonotariou, Aristides Lytra. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047390. |
medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. |
2006-11-21 |
2023-08-12 |
Not clear |
| George Tolis, Nicholas G Angelopoulos, Eugenia Katounda, Grigorios Rombopoulos, Victoria Kaltzidou, Dimitrios Kaltsas, Anthi Protonotariou, Aristides Lytra. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047390. |
somatostatin analogs control gh/insulin-like growth factor (igf)-1 excess, induce tumor shrinkage in a high proportion of patients, improve symptoms of acromegaly with relatively limited side effects and are successfully administered in patients not suitable for surgery. |
2006-11-21 |
2023-08-12 |
Not clear |
| George Tolis, Nicholas G Angelopoulos, Eugenia Katounda, Grigorios Rombopoulos, Victoria Kaltzidou, Dimitrios Kaltsas, Anthi Protonotariou, Aristides Lytra. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047390. |
finally, the link between the hormonal/biochemical and the psychiatric/psychological features of acromegaly, as well as a potential basis for positive effects of somatostatin analog therapy remain unclear. |
2006-11-21 |
2023-08-12 |
Not clear |
| A J van der Lely, John J Kopchic. Growth hormone receptor antagonists. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047392. |
the currently available long-acting somatostatin analogs normalize serum growth hormone (gh) levels and insulin-like growth factor-i levels in approximately 60% of patients with acromegaly. |
2006-11-21 |
2023-08-12 |
human |
| John P Monso. Is there still a role for radiotherapy in acromegaly? Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047393. |
the development of potent medical therapies for acromegaly (somatostatin analogues and the gh receptor antagonist) has called into question the role of radiotherapy in the treatment of this disease. |
2006-11-21 |
2023-08-12 |
Not clear |
| John P Monso. Is there still a role for radiotherapy in acromegaly? Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047393. |
however, even if the concept of primary, open-ended medical therapy for selected patients is accepted, reference to the success rates of surgery and response rates to somatostatin analogues indicates that approximately 10-20% of all patients with acromegaly will require consideration of radiotherapy for hormonal or tumour mass control. |
2006-11-21 |
2023-08-12 |
Not clear |
| Brian Tomlinson, Neil G Thomas, Irene W Lan, Manuel Barbanoj, Rosa M Antonijoan, Eva Drazna, Joaquim Ramis, Rosendo Obach, Concepción Perair. Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency. Clinical pharmacokinetics. vol 45. issue 10. 2006-11-14. PMID:16984213. |
the somatostatin analogue lanreotide is indicated for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumours. |
2006-11-14 |
2023-08-12 |
human |
| Deng-Huang Su, Kuo-Meng Liao, Huan-Wen Chen, Tien-Chun Chan. Long-term primary medical therapy with somatostatin analogs in acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 105. issue 8. 2006-10-26. PMID:16935768. |
long-term primary medical therapy with somatostatin analogs in acromegaly. |
2006-10-26 |
2023-08-12 |
Not clear |
| Deng-Huang Su, Kuo-Meng Liao, Huan-Wen Chen, Tien-Chun Chan. Long-term primary medical therapy with somatostatin analogs in acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 105. issue 8. 2006-10-26. PMID:16935768. |
here, we report two cases of acromegaly under treatment with somatostatin analogs alone for more than 10 years. |
2006-10-26 |
2023-08-12 |
Not clear |
| Marcello D Bronstei. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Frontiers of hormone research. vol 35. 2006-10-17. PMID:16809928. |
acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. |
2006-10-17 |
2023-08-12 |
Not clear |